Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2021-02-11
Target enrollment:
Participant gender:
Summary
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm,
Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and
tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients
with Uncontrolled Type-2 Diabetes Mellitus (T2DM).
Phase:
Phase 3
Details
Lead Sponsor:
Cadila Pharnmaceuticals
Collaborator:
New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India